title: Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer.
abstract: MUC1 is immunogenic in vivo and humoral and cellular immune responses against MUC1 have been detected in cancer patients. Our study explored the association of circulating anti-MUC1 antibodies with clinicopathological parameters or patients' survival of pancreatic cancer. Serum specimens from 36 patients with invasive ductal carcinoma of the pancreas were subjected to enzyme immunoassay for anti-MUC1 IgG or IgM antibodies. Serum levels of anti-MUC1 IgG antibodies were significantly correlated with survival time (p = 0.0004), whereas neither those of anti-MUC1 IgM nor anti-Galalpha(1,3)Gal IgG antibodies, the latter known as natural antibodies cross-reactive with MUC1, showed a given tendency. Some patients' sera with the higher antibody titer showed the reactivity with MUC1-transfectants of cultured pancreatic cancer cells, but not with MUC1-negative parental cells. When the samples were tentatively divided into 2 groups by the serum level of anti-MUC1 IgG antibodies, the survival of patients was significantly longer in the group with optical density >or=0.3 than in that with optical density <0.3 (p = 0.008). Circulating anti-MUC1 IgG antibody levels remained significant (HR, 0.03; 95% CI, 0.003-0.289; p = 0.0024) after multivariate analysis for pTNM stage, patient age and gender. These data suggest that circulating anti-MUC1-IgG antibody levels may be predictive for survival of pancreatic cancer patients.
authors.affiliation: Department of Clinical Laboratory Science, Yamaguchi University School of Medicine, Ube, Yamaguchi, Japan.
authors.forename: Yuichiro
authors.initials: Y
authors.lastname: Hamanaka
authors.forename: Yutaka
authors.initials: Y
authors.lastname: Suehiro
authors.forename: Mikiko
authors.initials: M
authors.lastname: Fukui
authors.forename: Kyoko
authors.initials: K
authors.lastname: Shikichi
authors.forename: Kohzoh
authors.initials: K
authors.lastname: Imai
authors.forename: Yuji
authors.initials: Y
authors.lastname: Hinoda
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000912:Antibodies, Neoplasm / Q000097:blood*; D001323:Autoantibodies / Q000097:blood*; D018270:Carcinoma, Ductal, Breast / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D005260:Female; D006801:Humans; D007124:Immunoenzyme Techniques; D007074:Immunoglobulin G / Q000097:blood*; D008297:Male; D008875:Middle Aged; D018396:Mucin-1 / Q000276:immunology*; D009361:Neoplasm Invasiveness; D010190:Pancreatic Neoplasms / Q000276:immunology* / Q000401:mortality / Q000473:pathology; D011379:Prognosis; D015996:Survival Rate; D014162:Transfection
chemical_list: D000912:Antibodies, Neoplasm; D001323:Autoantibodies; D007074:Immunoglobulin G; D018396:Mucin-1